The collaboration builds on an oligonucleotide supply agreement the partners signed in 2019 for Clear Labs' nanopore sequencing-based food safety testing.
The system is based on GNA's proprietary pulsed control amplification technology, which uses short electrical pulses to drive rapid amplification cycles.
The SARS-CoV-2 test, which runs on Cepheid's GeneXpert systems, is to detect SARS-CoV-2 nucleic acid in upper respiratory specimens such as nasal swabs.
Xprize said it selected the finalists from 219 semifinalists after conducting blind proficiency testing and judging a questionnaire reflecting each team's qualifications.
An analysis of SARS-CoV-2 genomes from early COVD-19 patients in Scotland shows the virus was introduced there multiple times, typically from continental Europe.
Q2 Solutions will run Adaptive's NGS-based immune cell receptor profiling assay for its pharma and biotech clients, potentially in COVID-19 vaccine trials.
The PCR-based test is designed to detect SARS-CoV-2 nucleic acid in upper respiratory specimens such as anterior nasal swabs collected by a healthcare provider.
Osang is seeking US Food and Drug Administration Emergency Use Authorization for its PCR-based SARS-CoV-2 diagnostic kit and plans to distribute it to US airports.
While SARS-CoV-2 test demand will likely remain strong well into 2021, the question of what to do with the built-up capacity in a post-COVID-19 environment looms.
The firm claims a rapid isothermal test has an LoD of 20 viral copies per milliliter while a saliva-based PCR test has an LoD of 2 copies per milliliter.
The PCR-based panel is designed to simultaneously detect SARS-CoV-2, influenza A and B, and respiratory syncytial virus, with results in less than two hours.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
